|
|
Vaccine Detail
|
Encepur |
| Vaccine Information |
- Vaccine Name: Encepur
- Target Pathogen: Tick-borne Encephalitis Virus (TBEV)
- Target Disease: Tick-borne Encephalitis
- Product Name: GlaxoSmithKline
- Manufacturer: Pfizer
- Type: Inactivated or "killed" vaccine
- Status: Licensed
- Host Species for Licensed Use: Human
- Antigen: Proteins of whole virus particle and viral non structural protein 1 (NS1) and E protein.(Salat et al., 2020)
- NS1
gene engineering:
- Type: Recombinant protein preparation
- Description: Inactivated
- Detailed Gene Information: Click Here.
- E
gene engineering:
- Type: Recombinant protein preparation
- Description: Inactivated
- Detailed Gene Information: Click Here.
- Preparation: ncepur Adults vaccines were processed using filter-aided sample preparation (FASP). , protein cysteine disulfide bonds were reduced in 0.1M dithiothreitol (DTT) in 8 M urea/0.1 M Tris/HCl (pH 8.5), and 50 mM iodoacetamide was used to alkylate cysteine residues (Salat et al., 2020).
- Immunization Route: Intramuscular injection (i.m.)
- Description: Encepur is a -virus formalin-inactivated TBEV vaccines avaliable in the European Union and European Economic Area. Vaccination induces neutralizing antibodies directed against the main antigenic determinant of the viral particle, the E protein.(Salat et al., 2020)
|
| Host Response |
|
|
| References |
|
|
|
